MX2021008919A - Dosis y administracion de anticuerpos anti-c5 para el tratamiento del sindrome uremico hemolitico atipico (shua). - Google Patents

Dosis y administracion de anticuerpos anti-c5 para el tratamiento del sindrome uremico hemolitico atipico (shua).

Info

Publication number
MX2021008919A
MX2021008919A MX2021008919A MX2021008919A MX2021008919A MX 2021008919 A MX2021008919 A MX 2021008919A MX 2021008919 A MX2021008919 A MX 2021008919A MX 2021008919 A MX2021008919 A MX 2021008919A MX 2021008919 A MX2021008919 A MX 2021008919A
Authority
MX
Mexico
Prior art keywords
ahus
antibodies
dosage
administration
treatment
Prior art date
Application number
MX2021008919A
Other languages
English (en)
Spanish (es)
Inventor
Xiang Gao
Rajendra Pradhan
Andrew Damokosh
Lori Payton
Christian Mix
Eugene Scott Swenson
Original Assignee
Alexion Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharma Inc filed Critical Alexion Pharma Inc
Publication of MX2021008919A publication Critical patent/MX2021008919A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
MX2021008919A 2019-01-25 2020-01-24 Dosis y administracion de anticuerpos anti-c5 para el tratamiento del sindrome uremico hemolitico atipico (shua). MX2021008919A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962796953P 2019-01-25 2019-01-25
PCT/US2020/014998 WO2020154626A1 (en) 2019-01-25 2020-01-24 Dosage and administration of anti-c5 antibodies for treatment of atypical hemolytic uremic syndrome (ahus)

Publications (1)

Publication Number Publication Date
MX2021008919A true MX2021008919A (es) 2021-11-04

Family

ID=69740563

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021008919A MX2021008919A (es) 2019-01-25 2020-01-24 Dosis y administracion de anticuerpos anti-c5 para el tratamiento del sindrome uremico hemolitico atipico (shua).

Country Status (18)

Country Link
US (1) US20220235121A1 (https=)
EP (1) EP3914617B1 (https=)
JP (2) JP7511566B2 (https=)
KR (2) KR20210119420A (https=)
CN (2) CN117838856A (https=)
AU (3) AU2020213121A1 (https=)
BR (1) BR112021014472A2 (https=)
CA (1) CA3127797A1 (https=)
DK (1) DK3914617T3 (https=)
ES (1) ES2980453T3 (https=)
FI (1) FI3914617T3 (https=)
HU (1) HUE067202T2 (https=)
LT (1) LT3914617T (https=)
MX (1) MX2021008919A (https=)
PL (1) PL3914617T3 (https=)
PT (1) PT3914617T (https=)
SI (1) SI3914617T1 (https=)
WO (1) WO2020154626A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3024618A1 (en) 2016-05-27 2017-11-30 Alexion Pharmaceuticals, Inc. Methods for treatment of refractory generalized myasthenia gravis
DK3658184T5 (da) 2017-07-27 2024-08-26 Alexion Pharma Inc Højkoncentrerede anti-c5-antistofformuleringer
CN118512588A (zh) 2017-10-26 2024-08-20 亚力兄制药公司 用于治疗阵发性夜间性血红蛋白尿(pnh)和非典型溶血性尿毒症综合征(ahus)的抗c5抗体的剂量和施用
EP3802593B1 (en) 2018-05-31 2024-09-11 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) in pediatric patients
EP3802603A1 (en) 2018-06-04 2021-04-14 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treatment of atypical hemolytic uremic syndrome (ahus) in pediatric patients
US12312394B2 (en) 2018-06-28 2025-05-27 Alexion Pharmaceuticals, Inc. Methods of producing anti-C5 antibodies
EP3873602B1 (en) 2018-10-30 2023-12-06 Alexion Pharmaceuticals, Inc. Subcutaneous dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh)
EP4281472A1 (en) * 2021-01-22 2023-11-29 Alexion Pharmaceuticals, Inc. Methods of treating complement mediated thrombotic microangiopathy using an anti-c5 antibody
MX2023013148A (es) * 2021-05-07 2023-11-28 Novartis Ag Iptacopan para el tratamiento del sindrome uremico hemolitico atipico.

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
PY09026846A (es) 2008-08-05 2015-09-01 Novartis Ag Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5
WO2014099546A1 (en) 2012-12-19 2014-06-26 Promerus, Llc Process for the preparation of high purity norbornene alkanols and derivatives thereof
NZ631007A (en) 2014-03-07 2015-10-30 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
BR112017011235A2 (pt) 2014-12-19 2018-02-06 Chugai Pharmaceutical Co Ltd anticorpos anti-c5 e métodos de uso
EP3402816A1 (en) * 2016-01-11 2018-11-21 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treatment
CN116769024A (zh) 2016-06-14 2023-09-19 瑞泽恩制药公司 抗c5抗体及其用途
DK3658184T5 (da) * 2017-07-27 2024-08-26 Alexion Pharma Inc Højkoncentrerede anti-c5-antistofformuleringer
CN118512588A (zh) * 2017-10-26 2024-08-20 亚力兄制药公司 用于治疗阵发性夜间性血红蛋白尿(pnh)和非典型溶血性尿毒症综合征(ahus)的抗c5抗体的剂量和施用
EP3802603A1 (en) * 2018-06-04 2021-04-14 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treatment of atypical hemolytic uremic syndrome (ahus) in pediatric patients

Also Published As

Publication number Publication date
JP2024120942A (ja) 2024-09-05
EP3914617A1 (en) 2021-12-01
AU2026200805A1 (en) 2026-02-26
AU2020213121A1 (en) 2021-08-12
LT3914617T (lt) 2024-05-27
CA3127797A1 (en) 2020-07-30
DK3914617T3 (da) 2024-05-27
JP2022518507A (ja) 2022-03-15
WO2020154626A1 (en) 2020-07-30
SI3914617T1 (sl) 2024-06-28
EP3914617B1 (en) 2024-03-13
CN117838856A (zh) 2024-04-09
JP7511566B2 (ja) 2024-07-05
AU2024266818B2 (en) 2026-02-19
HUE067202T2 (hu) 2024-10-28
JP7823117B2 (ja) 2026-03-03
PT3914617T (pt) 2024-05-31
AU2024266818A1 (en) 2025-01-02
KR20250016490A (ko) 2025-02-03
ES2980453T3 (es) 2024-10-01
PL3914617T3 (pl) 2024-08-05
FI3914617T3 (fi) 2024-05-24
US20220235121A1 (en) 2022-07-28
KR20210119420A (ko) 2021-10-05
CN113614105A (zh) 2021-11-05
BR112021014472A2 (pt) 2021-09-21

Similar Documents

Publication Publication Date Title
MX2021008919A (es) Dosis y administracion de anticuerpos anti-c5 para el tratamiento del sindrome uremico hemolitico atipico (shua).
CO2020004831A2 (es) Dosis y administración de anticuerpos antic-c5 para el tratamiento de pacientes con glomerulonefritis membranoproliferativa
CO2020004838A2 (es) Dosis y administración de anticuerpos anti-c5 para el tratamiento de la hemoglobinuria paroxística nocturna (hpn) y el síndrome hemolítico urémico atípico (shua)
WO2017123636A8 (en) Dosage and administration of anti-c5 antibodies for treatment
CY1122245T1 (el) Pd-1 αντισωμα, θραυσμα δεσμευσης αντιγονου αυτου, και ιατρικη εφαρμογη αυτου
DOP2020000245A (es) Anticuerpos il-11
MX2020012905A (es) Proteínas de unión multiespecíficas y mejoras con estas.
EP3689909A4 (en) Tigit antibody, antigen-binding fragment thereof, and medical use thereof
MX2019011117A (es) Anticuerpo b7-h3, fragmento de union a antigeno de los mismos y uso medico de los mismos.
JOP20170004B1 (ar) الأجسام المضادة لببتيد بيتا النشوي مضاد N3pGlu واستخداماته
MX2020002750A (es) Anticuerpo il-6r y fragmento de union a antigeno y uso medico.
CL2021000483A1 (es) Métodos y composiciones para el tratamiento de sujetos que padecen artritis reumatoide.
MX2021009789A (es) Dosificacion y administracion de anticuerpos anti-c5 para el tratamiento de miastenia gravis generalizada.
BR112020015498A8 (pt) Anticorpos anti-pd-1
MX2021004351A (es) Metodo para el tratamiento de miastenia grave.
MX2022006784A (es) Formulaciones de anticuerpos anti-pd-l1.
EP4006055A4 (en) ANTI-BCMA ANTIBODIES, ANTIGEN-BINDING FRAGMENT THEREOF AND MEDICAL USE THEREOF
MX2018009264A (es) Anticuerpo de trombina, fragmento de antigeno y sus usos farmaceuticos.
MX2020003034A (es) Anticuerpo il-5, fragmento de union a antigeno del mismo y su aplicacion medica.
MX2019007107A (es) Anticuerpo anti-adrenomedulina (adm) o fragmento de anticuerpo anti-adm o supercontigo sin ig anti-adm para su uso en intervencion y terapia de congestion en un paciente con necesidad del mismo.
EA201792312A1 (ru) Конструкции на основе калихеамицина и способы их применения
HUE052528T2 (hu) Anti szklerosztin antitest, antigénkötõ fragmens és annak orvosi használata
MX2020004074A (es) Producto de combinacion para el tratamiento de cancer.
EA201992348A1 (ru) АНТИГЕН-СВЯЗЫВАЮЩИЕ БЕЛКИ, ВЗАИМОДЕЙСТВУЮЩИЕ С Jagged1
EA202190504A1 (ru) Способы лечения псориаза